Screening for spina bifida cystica. A cost-benefit analysis.
The costs and economic benefits are examined of introducing a programme for the mass-screening of pregnancies for the detection and abortion of fetuses with spina bifida cystica. A benefit-cost index is derived, and the possible effects on it of making different input assumptions are discussed. It is considered that, on economic grounds, screening may be worthwhile only in populations in which the incidence of spina bifida is high.
D000649:Amniocentesis; D000757:Anencephaly / Q000453:epidemiology; D003362:Cost-Benefit Analysis; D004180:Direct Service Costs; D005260:Female; D006801:Humans; D008017:Life Expectancy; D008403:Mass Screening; D011247:Pregnancy; D037841:Pregnant People; D011296:Prenatal Diagnosis; D012606:Scotland; D012943:Social Security; D016135:Spinal Dysraphism / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control*; D014463:Ultrasonography; D000509:alpha-Fetoproteins / Q000032:analysis
D000509:alpha-Fetoproteins